Group One Trading, L.P. Alzamend Neuro, Inc. Transaction History

Group One Trading, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$0.49 - $0.77 $1,109 - $1,743	2,264 Added 80.91%	5,062 $2,000
Q1 2023 May 12, 2023	SELL	$0.37 - $0.71 $3,872 - $7,430	-10,465 Reduced 78.9%	2,798 $1,000
Q4 2022 Feb 09, 2023	SELL	$0.53 - $222.0 $17,097 - $7.16 Million	-32,260 Reduced 70.87%	13,263 $7,000
Q3 2022 Nov 09, 2022	BUY	$0.88 - $178.5 $29,762 - $6.04 Million	33,821 Added 289.02%	45,523 $54,000
Q2 2022 Aug 11, 2022	BUY	$0.82 - $1.2 $9,595 - $14,042	11,702 New	11,702 $10,000
Q1 2022 May 12, 2022	SELL	$0.91 - $2.23 $39,033 - $95,653	-42,894 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$1.9 - $3.08 $68,749 - $111,446	36,184 Added 539.25%	42,894 $82,000
Q3 2021 Nov 12, 2021	BUY	$2.28 - $7.68 $15,298 - $51,532	6,710 New	6,710 $21,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.